RDB07688 - pGL4-phLEP

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL4-phLEP (#RDB07688)

Promoter collection, Human LEP promoter

Alternative name	U3005-5
Clone info.	PCR amplified human LEP promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 128239886 to 128241342(NC_000007.14 ); relatively -1392 to +65, where +1 corresponds to 1 nt of NM_000230.3.
Comment	PCR cloning, forward primer: tcaccaacgtcatttgcagt; reverse primer: agcagagaaggaggaaggag. Entire sequence of promoter region has not been confirmed.
Vector backbone	pGL4.10 [Luc2] (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Human leptin genomic DNA
Depositor\|Developer	DNA Bank, \|

Remarks, protocol and/or map (pdf)	RDB07688.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	謝辞の表明を必要とする。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07688	pGL4-phLEP	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL4-phLEP was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07688).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07688_A6C1p1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4-4174F Sequence file: RDB07688_A6C1a.seq
>07688_07688_A6C1_2_pGL4-4174F_C04_07.ab1 1 GTGGGTCAGA CATTTCTCTG GCCTAACTGG CCGGTACCTG AGCTCGCTAG CCTCGAGGAT 61 TCACCAACGT CATTTGCAGT TCCCCGCTTT ATGTTATGGG TTTTGTTTTG TTTTGTTTTT 121 TTTATTGAGA CAGAGTTTCA CTCTTGTTGC CCAGGCTGTA GTGCAATGGT CTGATCTTGG 181 CTCACTGCAA CCTCCACTTC CCAGGTTCAA GCCATTCTCC TGCCTCAGCC TCTCAAGTAG 241 CTGGGATTAC AGACACTCAC CACCACACCT GGCTAATTTT GTATTTTTAG TAGAGATGAG 301 GTTTCACCAT GTTGGCCAGG CTGGTCTCGA AATCCTGACC TCAGGTGATC CACCCACCTT 361 GGCCTCCCAA AGTGCTGGGA TTACAGGCTT GAGCTACCAC GCCTGGCTGG GTTGGTTCTC 421 AATGGAGTGG TTTGTTTTTG GAGCTGCTCT GCGCAGTGGG GACCAGAATA GGCCTGGGTT 481 CCTAGCCCAT TGCTATTCCT TACCAGCTGT GGATTCTAAG GAAAGTCATT TAACCTCGCT 541 GGACCTTAGA TTCCTCATCC CTGAAGCCCA AGGGTAAAAC AAAACAAAAC AAAACAAAAC 601 AAACCAACCC ATCATGTAAA GCGGGGAACT ACAAACGAAT ACAGGTGAAA CATGCCTACC 661 ACACCACTCA CAGGCTATGA TGACAAAAAG TGGGCTACAT CTGGGACCAA CCC //
Primer: pGL4-136R Sequence file: RDB07688_A6C1b.seq
>07688_07688_A6C1_2_pGL4-136R_D04_10.ab1 1 GAGGTCTAGT TTGGCATCTT GCATGGTGGC TTTACCAACA GTACCGGATT GCCAAGCTTG 61 GCCGCCGAGG CCAGATCTTG ATAGCAGAGA AGGAGGAAGG AGCGCGCCGG GGCCTTACCT 121 TGCAACCGCT GGCGCTGCGA TTCCTACGGG GCTCCATGCC TGCCCGCCCC TCTTATAGCG 181 GCCCGATCAC AACTTGCGCA ACTGCCCCGC AGGCCCCGGC GCATTTCTAG CGCCAGCTCC 241 CGCCCCGCCC CTCAGGGTAG CGACGTGCCG GGCGGCTGCT AGCCCTGGGC CCGCAGTGTG 301 CACCTCGCGG GGCCTCGAGG GAGGGCCTCG GCGCTCCAGG AGCCACGCGC GCACCCTTGG 361 GTACCTCCCA AAAATTTGGG GGTGGCTGGT AGGAGCGAGA AATCCTTGAT GTCCCTCCAG 421 AGGCTCCGGC GCGACTATGG CGCAAGGACC AGCCCCTTGG GAAGGTGCTT CGAGCCGCGC 481 GGGGCGCGGT CGGGGCGGGG GTGGCTGTGA GGGGCTCCGC GGAGCGGGCT GGGGCATACG 541 GCTGCGCCCT CGTTGGTCCT GGCGCGGCTT CGGGGTGGGA GCGAATCGGG ACTCGGCCCC 601 GACGGCCCTG GACGCCAGGG AAGCCCAGGG TTAGAGGGAG CGGCCCGCAG TGCGCCAGGC 661 TCCCCGACCC AGATTGCGGG GTTGGGGGTT CTGAAGTCCC ACCCCTTCTC TGGCACGCGG 721 AGAATCGAGT TCCAAGCCTC AGGGCAAGTT GTCTCTGGCT GGCACCCCAG GGAGTGCACA 781 CTCTCTGGAG GGCTCCAGGC GGGCACTGTG GCCTTTGGGG ACACTCTGGA CATACTGTGG 841 GTCTCCATCC TCAACTCCGT ATTTCCTACG TACAAAGTGG GGGGTTGGGG GGGGTGGTCC 901 CAGATGTAGC CACGTTTTTT GTCATCATAG CCTGTGAGTG GTGTGGTAGG CATGTTTCAC 961 CTGTATCGTT TGTAGTTTCC CCGCTTTACA TGATGGGGTT TGGTTTGTTT TGTTTTGTTT 1021 TTGTTTTTGT TTTACCCTTT GGGGCTTCAT GGATGAGAAT CTAACGTCCC AGCGAGGGTT 1081 AAATTGACCT TCGTAGAACT CCACAGCTGG TAAGGAAATT AAGGCCTAT //
Primer: pAxCALNL_F1 Sequence file: RDB07688_A6C1c.seq
>07688_07688_A6C1_2_pAxCALNL_F1_E04_13.ab1 1 TAATTATCTT ATCATGTCTG CTCGAGCGGC CGGCCGCCCC GACTCTAGAA TTATTACACG 61 GCGATCTTGC CGCCCTTCTT GGCCTTAATG AGAATCTCGC GGATCTTGCG GGCGTCCAAC 121 TTGCCGGTCA GTCCTTTAGG CACCTCGTCC ACGAACACAA CACCACCGCG CAGCTTCTTG 181 GCGGTTGTAA CCTGGCTGGC CACATAGTCC ACGATCTCCT TCTCGGTCAT GGTTTTACCG 241 TGTTCCAGCA CGACGACTGC GGCGGGCAGC TCGCCGGCAT CGTCGTCGGG CAGGCCGGCG 301 ACCCCGGCGT CGAAGATGTT GGGGTGTTGC AGCAGGATGC TCTCCAGTTC GGCTGGGGCT 361 ACCTGGTAGC CCTTGTATTT GATCAGGCTC TTCAGCCGGT CCACGATGAA GAAGTGCTCG 421 TCCTCGTCCC AGTAGGCGAT GTCGCCGCTG TGCAGCCAGC CGTCCTTGTC GATGAGAGCG 481 TTTGTAGCCT CGGGGTTGTT AACGTAGCCG CTCATGATCA TGGGGCCACG GACGCACAGC 541 TCGCCGCGCT GGTTCACACC CAGTGTCTTA CCGGTGTCCA AGTCCACCAC CTTAGCCTCG 601 AAGAAGGGCA CCACCTTGCC TACTGCGCCA GGCTTGTCGT CCCCTTCGGG GGTGATCAGA 661 ATGGCGCTGG TTGTTTCTGT CAGGCCGTAG CCCTGGCGGA TGCCTGGTAG GTGGAAGCGT 721 TTGGCCACGG CCTCACCTAC CTCCTTGCTG AGCGGCGCCC CGCCGCTGGC GATCTCGTGC 781 AAGTTGCTTA GGTCGTACTT GTCGATGAGA GTGCTCTTAG CGAAGAAGCT AAATAGTGTG 841 GGCACCAGCA GGGCAGATTG AATCTTATAG TCTTGCAAGC TGCGCAAGAA TAGCTCCTCC 901 TCGAAAGCGG TACATGAGCA CGACCCGAAA GCCGCAGATC AAGTAGCCCA GCGTGGTGAA 961 CATGCCGAAG CCGTGGGTGA AATGGCACCA CGCTGAGATA GCGGTGTCGG GGATGATCTG 1021 GGTTGCCGAG ATGGGGGGTC GCGGCATGAC TGAATTCGGA CACAGCCGGT TGCCGGATGC 1081 GGCTATGCTA CGTCCTTGGG GCCACTCGGC TACCTGCTAC TAATCCTGGG T //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

Resource search

Link

Other resources in our bank

human leptin

External Database
Human leptin

Reference sequence